Angina (Angina Pectoris) - Pipeline Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 71
Inquire Before Buying

Angina (Angina Pectoris) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Pipeline Review, H2 2018, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape.

Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Angina (Angina Pectoris) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 2, 1, 1 and 2 respectively.

Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris) (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Angina (Angina Pectoris) (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Angina (Angina Pectoris) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Angina (Angina Pectoris) (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Angina (Angina Pectoris) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Angina (Angina Pectoris) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Angina (Angina Pectoris) - Overview
Angina (Angina Pectoris) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Angina (Angina Pectoris) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Angina (Angina Pectoris) - Companies Involved in Therapeutics Development
Angionetics Inc
Caladrius Biosciences Inc
G. Pohl-Boskamp GmbH & Co KG
Hemostemix Inc
ID Pharma Co Ltd
Kuhnil Pharmaceutical Co Ltd
TSH Biopharm Corporation Ltd
ViroMed Co Ltd
XyloCor Therapeutics Inc
Angina (Angina Pectoris) - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alferminogene tadenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-14RfA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KI-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitroglycerin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranolazine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Angina - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Angina (Angina Pectoris) - Dormant Projects
Angina (Angina Pectoris) - Discontinued Products
Angina (Angina Pectoris) - Product Development Milestones
Featured News & Press Releases
Jul 18, 2018: Hemostemix announces first U.S. Patients treated in phase II clinical trial
Jun 19, 2018: Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina
May 08, 2017: FDA Grants Fast Track designation to XyloCor Therapeutics Lead Candidate XC001
Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease
Sep 26, 2016: Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO (Nitroglycerin) Sublingual Powder in the U.S.
Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
Aug 31, 2016: Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO (Nitroglycerin) Sublingual Powder
Jun 14, 2016: Espero Pharmaceuticals Receives FDA Approval for GONITRO (Nitroglycerin) Sublingual Powder
May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
May 16, 2012: Ark Completes Dose Ranging Phase I Section Of Refractory Angina Clinical Study
Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Angina (Angina Pectoris), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Angina (Angina Pectoris) - Pipeline by Angionetics Inc, H2 2018
Angina (Angina Pectoris) - Pipeline by Caladrius Biosciences Inc, H2 2018
Angina (Angina Pectoris) - Pipeline by G. Pohl-Boskamp GmbH & Co KG, H2 2018
Angina (Angina Pectoris) - Pipeline by Hemostemix Inc, H2 2018
Angina (Angina Pectoris) - Pipeline by ID Pharma Co Ltd, H2 2018
Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2018
Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, H2 2018
Angina (Angina Pectoris) - Pipeline by ViroMed Co Ltd, H2 2018
Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, H2 2018
Angina (Angina Pectoris) - Dormant Projects, H2 2018
Angina (Angina Pectoris) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Angina (Angina Pectoris) - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Angina (Angina Pectoris), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 196
    Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease Peripheral Vascular Disease - Pipeline Review, H2 2018, provides an overview of the Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline landscape. Peripheral vascular disease (PVD) refers to diseases of the blood ve......
  • Critical Limb Ischemia - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 142
    Critical Limb Ischemia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2018, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape. Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that resul......
  • Atherosclerosis - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 244
    Atherosclerosis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H2 2018, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape. Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts......
  • Stroke - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 544
    Stroke - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H2 2018, provides an overview of the Stroke (Cardiovascular) pipeline landscape. Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear sudd......
  • Arterial Thrombosis - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 54
    Arterial Thrombosis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arterial Thrombosis - Pipeline Review, H2 2018, provides an overview of the Arterial Thrombosis (Cardiovascular) pipeline landscape. Arterial thrombosis is a blood clot that develops in an artery. Symptoms include lack of pulse, pain or spasms in the muscles, pale skin and coldness. Depending on where the clot forms, art......
  • Global Congestive Heart Failure Drugs Market Size, Status and Forecast 2018-2025
    Published: 06-Sep-2018        Price: US 3900 Onwards        Pages: 109
    This report focuses on the global Congestive Heart Failure Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Congestive Heart Failure Drugs development in United States, Europe and China. In 2017, the global Congestive Heart Failure Drugs market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025. The key players covered in this study......
  • Global Myocardial Infarction Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 30-Aug-2018        Price: US 3480 Onwards        Pages: 130
    Myocardial infarction, commonly known as heart attack, occurs due to reduced blood flow to a part of the heart, causing damage to the heart muscle. The medications, which are used to treat heart attacks are known as myocardial infarction drugs. The reduced blood flow further causes blockage in the supply of oxygen to the heart, which is due to atherosclerosis, a process in which the plaque is formed on the inside wall of the coronary vein or one of its minor branches. Myocardial infraction occur......
  • Global and Chinese Simvastatin Industry, 2018 Market Research Report
    Published: 29-Aug-2018        Price: US 3000 Onwards        Pages: 144
    The 'Global and Chinese Simvastatin Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Simvastatin industry with a focus on the Chinese market. The report provides key statistics on the market status of the Simvastatin manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, appli......
  • Global Heart Failure Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 27-Aug-2018        Price: US 3480 Onwards        Pages: 135
    The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast pe......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs